1. Home
  2. TARS vs NVTS Comparison

TARS vs NVTS Comparison

Compare TARS & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

SELL

Current Price

$69.88

Market Cap

3.6B

Sector

Health Care

ML Signal

SELL

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

SELL

Current Price

$8.99

Market Cap

3.0B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
TARS
NVTS
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.0B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TARS
NVTS
Price
$69.88
$8.99
Analyst Decision
Strong Buy
Hold
Analyst Count
10
8
Target Price
★ $99.80
$14.08
AVG Volume (30 Days)
589.3K
★ 12.0M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 48.21
N/A
EPS
★ N/A
N/A
Revenue
★ $451,360,000.00
$45,916,000.00
Revenue This Year
$61.17
$3.87
Revenue Next Year
$26.47
$55.68
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 146.71
N/A
52 Week Low
$53.89
$6.85
52 Week High
$91.53
$34.17

Technical Indicators

Market Signals
Indicator
TARS
NVTS
Relative Strength Index (RSI) 39.09 29.76
Support Level $69.47 $7.65
Resistance Level $73.45 $9.64
Average True Range (ATR) 2.85 0.66
MACD -0.68 -0.28
Stochastic Oscillator 0.91 5.55

Price Performance

Historical Comparison
TARS
NVTS

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

Share on Social Networks: